{
  "denotations": [
    {
      "id": "T1",
      "obj": "Chemical",
      "span": {
        "begin": 137,
        "end": 147
      }
    },
    {
      "id": "T2",
      "obj": "Chemical",
      "span": {
        "begin": 150,
        "end": 163
      }
    },
    {
      "id": "T3",
      "obj": "Disease",
      "span": {
        "begin": 193,
        "end": 199
      }
    },
    {
      "id": "T4",
      "obj": "Disease",
      "span": {
        "begin": 204,
        "end": 212
      }
    },
    {
      "id": "T6",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 259,
        "end": 264
      }
    },
    {
      "id": "T7",
      "obj": "Disease",
      "span": {
        "begin": 107,
        "end": 113
      }
    },
    {
      "id": "T8",
      "obj": "Chemical",
      "span": {
        "begin": 137,
        "end": 163
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "22753902_3",
  "text": "PATIENTS AND METHODS : Younger ( < 60 years ; n = 175 ) and older ( > = 60 years ; n = 225 ) patients with CN-AML treated with intensive cytarabine / anthracycline -based first-line therapy on Cancer and Leukemia Group B protocols were centrally analyzed for RUNX1 mutations by polymerase chain reaction and direct sequencing and for established prognostic gene mutations ."
}
